Watch NVCT. Know when insiders buy.
One email the day a filing lands. Free.
NVCT
Nuvectis Pharma, Inc.
21.07
−0.91 −4.14%
USD · close Sep 23
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
9
FLAG · shorts 9
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $686.5MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$27.8MNET CASH —52W 5.65 – 28.53SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$7.2M | −$7M | — | -0.30 | −$4.5M | — | — | Aug 4 |
| Q1 2026 · Mar 31 | — | — | — | −$6.3M | −$6M | — | -0.26 | −$6.5M | — | — | Aug 4 |
| Q4 2025 · Dec 31derived | — | — | — | −$7.6M | −$7.3M | — | -0.31 | −$4M | — | — | Feb 11 |
| Q3 2025 · Sep 30 | — | — | — | −$7.8M | −$7.5M | — | -0.44 | −$4.5M | — | — | Nov 4 |
| Q2 2025 · Jun 30 | — | — | — | −$6.6M | −$6.3M | — | -0.30 | −$3.4M | — | — | Aug 4 |
| Q1 2025 · Mar 31 | — | — | — | −$5.6M | −$5.3M | — | -0.27 | −$4.2M | — | — | Aug 4 |
| Q4 2024 · Dec 31derived | — | — | — | −$6.4M | −$6.2M | — | -0.36 | −$2.5M | — | — | Feb 11 |
| Q3 2024 · Sep 30 | — | — | — | −$4.4M | −$4.2M | — | -0.24 | −$2.4M | — | — | Nov 4 |
| Q2 2024 · Jun 30 | — | — | — | −$4.6M | −$4.4M | — | -0.26 | −$3M | — | — | Nov 4 |
| Q1 2024 · Mar 31 | — | — | — | −$4.4M | −$4.2M | — | -0.25 | −$4.4M | — | — | Nov 4 |
| Q4 2023 · Dec 31derived | — | — | — | −$6.9M | −$6.6M | — | -0.41 | −$3.9M | — | — | Feb 25 |
| Q3 2023 · Sep 30 | — | — | — | −$6.2M | −$5.9M | — | -0.37 | −$3.2M | — | — | Nov 5 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$27.6M | −$26.4M | — | -1.32 | −$16M | — | — | — | — |
| FY2024 · to Dec 31 | — | — | −$19.8M | −$19M | — | -1.11 | −$12.2M | — | — | — | — |
| FY2023 · to Dec 31 | — | — | −$22.9M | −$22.3M | — | -1.43 | −$16M | — | — | — | — |
| FY2022 · to Dec 31 | — | — | −$19.2M | −$19.1M | — | -1.51 | −$13.6M | — | — | — | — |
| FY2021 · to Dec 31 | — | — | −$12.9M | −$12.9M | — | -3.02 | −$9.5M | — | — | — | — |
Every number comes from Nuvectis Pharma, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.